Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 261

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 261
---
 December
31, 2025, we will not be eligible to use any existing registration statement on Form S-3, in each case, that would allow us to continuously
incorporate by reference our SEC reports into the registration statement, or to use “shelf” registration statements to conduct
offerings, until approximately one year from the date we regained (and maintain) status as a current and timely filer. Until such time,
if we determine to pursue an offering, we would be required to conduct the offering on an exempt basis, such as in accordance with Rule
144A, or file a registration statement on Form S-1. Using a Form S-1 registration statement for a public offering would likely take significantly
longer than using a registration statement on Form S-3 and increase our transaction costs, and could, to the extent we are not able to
conduct offerings using alternative methods, adversely impact our liquidity, ability to raise capital or complete acquisitions in a timely
manner. The use of Form S-1 would also prevent us from conducting offerings on a “shelf basis,” limiting our flexibility as
to the terms, timing or manner of any such offering.

50

We cannot guarantee that
in the future our reporting will always be timely. If we are unable to satisfy SEC filing deadlines or otherwise provide disclosures
of material information on a timely basis, stockholders and potential investors in our Common Stock may have incomplete information about
our business and results of operations, which may impact their ability to make an informed investment decision, result in a reduction
in the trading price, trading volume or analyst coverage of our Common Stock or expose us to potential liability.

Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds

On July 18, 2025, the Company
sold an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600 in an additional closing, and the Company
received net proceeds of $320,801.

During the three months ended
September 30, 2025, the Company sold 253,682 shares of common stock of the Company for net proceeds of $1,278,217 under the July 2025
Keystone Purchase Agreement.

On July 18, 2025, the
Company converted 53 shares of Series C Preferred Stock into 10,600 shares of common stock and in September 2025, 200 shares of
Series D Preferred Stock into 37,314 shares of common stock.